Researcher
Wendy De Roock
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 2006 → 31 Aug 2010
Publications
1 - 10 of 11
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis(2010)
Authors: Wendy De Roock, Bart Claes, Eric Van Cutsem, Diether Lambrechts, Sabine Tejpar
Pages: 753 - 762 - Predictors of Benefit in Colorectal Cancer Treated With Cetuximab: Are We Getting "Lost in TranslationAL"? Reply(2010)
Authors: Bart Jacobs, Wendy De Roock, Bart Claes, Sabine Tejpar
Pages: E175 - E176 - Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab(2009)
Authors: Bart Jacobs, Wendy De Roock, Robin Van Oirbeek, Steffen Fieuws, Gert De Hertogh, Eric Van Cutsem, Sabine Tejpar
Pages: 5068 - 5074 - Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)(2009)
Authors: Wendy De Roock, Hans Prenen, Eric Van Cutsem, Sabine Tejpar
Pages: 1375 - 1382 - PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer(2009)
Authors: Hans Prenen, Bart Jacobs, Wendy De Roock, Bart Claes, Diether Lambrechts, Eric Van Cutsem, Sabine Tejpar
Pages: 3184 - 3188 - K-ras mutations and cetuximab in colorectal cancer(2009)
Authors: Wendy De Roock, Diether Lambrechts, Sabine Tejpar
Pages: 834 - 4 - Clinical biomarkers in oncology: focus on colorectal cancer(2009)
Authors: Wendy De Roock, Sabine Tejpar
Pages: 103 - 114 - Amphiregulin and Epiregulin expression in primary colorectal cancer identifies a subgroup of patients that will respond to EGFR inhibition(2008)
Authors: Bart Jacobs, Robin Van Oirbeek, B Biesmans, Steffen Fieuws, Wendy De Roock, Joris De Schutter, Y Humblet, M Peeters, Eric Van Cutsem, Sabine Tejpar
Pages: 31 - 31 - DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease(2008)
Authors: Wendy De Roock, M Janssens, B Biesmans, B Jacobs, J De Schutter, Y Humblet, M Peeters, Eric Van Cutsem, Peter Marynen, Sabine Tejpar
Pages: 33 - 33 - Clinical usefulness of EGFR gene copy number as a predicitive marker in colorectal cancer patients with cetuximab: a fluorescent in situ hybridization study(2008)
Authors: Steffen Fieuws, Gert De Hertogh, Wendy De Roock, Maria Debiec-Rychter, Eric Van Cutsem, Sabine Tejpar
Pages: 5869 - 5876